AKELOS INC.

NEW YORK, NY · Founded 2018 · Biotech · Private

Non-narcotic small-molecule drugs targeting HCN1 ion channels for neuropathic pain treatment

Claim this profile

Follows are private to you and power your alerts

Updated · akelosinc.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2018
Latest Form D
$1.5M, Mar 2026
Total capital
$2.5M
Federal grants
$699K
2 awards · 2022–2023
Rank in peer group#110 of 502
Private capital raised
$1.8M
4 Form D · last Mar 2026
7 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20182020202220242026FEDERAL ↑EQUITY ↓Cumulative $2.5M$349K$349K1st Form D$295K2nd Form D$25K3rd Form D$6K4th Form D$1.5M
20182020202220242026FEDERAL ↑EQUITY ↓Cumulative $2.5M$349K$349K1st Form D$295K4th Form D$1.5M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$1.5M
  • Federal grantHealth and Human S · Phase II · Optimization of an HCN1-Selective Inverse Agonist for the Treatment of Peripheral Neuropathic Pain$349K
  • Private capital raisedForm D · SEC · 3rd filing$6K
  • Federal grantHealth and Human S · Phase II · Optimization of an HCN1-Selective Inverse Agonist for the Treatment of Peripheral Neuropathic Pain$349K
  • Private capital raisedForm D · SEC · 2nd filing$25K
  • Private capital raisedForm D · SEC · 1st filing$295K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#110 · top 22%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Steven FoxResearcherExecutive Officer, DirectorLinked by $349K in grants as PI

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .